

MarketVue®

Diabetic Retinopathy

June 2021



MarketVue®: Diabetic Retinopathy

UNDERSTAND THE DIABETIC RETINOPATHY MARKET

MarketVue market landscape reports combine primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.

Every **MarketVue** includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Methodology: Research is supported by 3 qualitative interviews with key opinion leaders (U.S. Retina Specialists), a quantitative survey with 19 U.S. physicians and secondary research.

Geographies covered: United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

TOPICS COVERED

EPIDEMIOLOGY: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments

CURRENT TREATMENT: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment

UNMET NEEDS: Identify opportunities to address treatment or disease management gaps

PIPELINE ANALYSIS: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs

VALUE AND ACCESS: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Why MarketVue?

- **PMR-Driven** – Insights informed by qualitative interviews and/or quantitative surveys
- **Senior Team** – Experienced team members (10+ years in pharma market research) lead the research
- **Strategic** – Delivered in a concise and strategic report template vetted by pharmaceutical industry professionals
- **Fresh** – New reports or report refreshes delivered in as little as 15 business days



MarketVue®: Diabetic Retinopathy

UNDERSTAND THE DIABETIC RETINOPATHY MARKET

COMPANIES MENTIONED

- Regeneron Pharmaceuticals
- Novartis
- Hoffmann-La Roche
- Adverum Biotechnologies
- Regenxbio
- Oxurion
- Graybug Vision
- Kubota Vision
- Opthea

DRUGS MENTIONED

- Aflibercept (Eylea)
- Ranibizumab (Lucentis)
- Bevacizumab (Avastin)
- Faricimab
- Ranibizumab port delivery system
- Brolucizumab (Beovu)
- RGX-314
- ADVM-022
- THR-149
- GB-102
- Emixustat
- OPT-302
- THR-687

MarketVue®: Diabetic Retinopathy

Table of Contents

1. DISEASE OVERVIEW	4
Blood vessel impairment underlies vision impairment in diabetic retinopathy	4
Hallmarks of diabetic retinopathy	4
Figure 1.1. Stages of diabetic retinopathy	4
2. EPIDEMIOLOGY & PATIENT POPULATIONS	5
Disease definition	5
Figure 2.1. Diagnosed prevalent cases of diabetic retinopathy by region	5
Table 2.1. Diagnosed prevalent and drug-treated diabetic retinopathy patients in the US and EU5	5
Figure 2.2. Segmentation of total prevalent cases of diabetic retinopathy by severity	5
3. CURRENT TREATMENT	6 - 10
Treatment Goals	6
Figure 3.1. Treatment goals for diabetic retinopathy	6
Standard of Care	6
Figure 3.2. Patient share of anti-VEGF treatment	6
Table 3.1. Current anti-VEGF usage by retinal specialists	6
Treating Physicians	7
Referring Physicians	7
Figure 3.3. Diagnosis and treatment flow for diabetic retinopathy	8
Must-know treatment dynamics for diabetic retinopathy	9
Barriers to patient care	9
Figure 3.4. Percent of retina specialists rating factor as "impactful"	9
Figure 3.5. Potential timeline of diabetic retinopathy market evolution	10
Is earlier treatment with current therapies on the horizon? Not so fast.	10
Figure 3.6. Retina specialist experimentation with anti-VEGF for NPDR	10
4. UNMET NEED	11 - 12
Treatment-related unmet needs	11
Figure 4.1. Top unmet needs in diabetic retinopathy	11
Figure 4.2. Percentage of retina specialists ranking unmet need in their top two	11

MarketVue®: Diabetic Retinopathy

Table of Contents

Unmet need by type of diabetic retinopathy	12
Figure 4.3. Percentage of retina specialists citing extremely high unmet need by disease type	12
Early prevention and reversal of disease progression	12
5. PIPELINE ANALYSIS	13 - 15
Overview	13
Figure 5.1. Number of emerging therapies addressing unmet needs in diabetic retinopathy	13
Gene therapy has caught the eye of retinal specialists	13
Figure 5.2. Percent of retina specialists rating target/approach as "promising"	13
Table 5.1. Emerging therapies in clinical development for diabetic retinopathy	14
Retina specialists' pipeline knowledge	15
Figure 5.3. Percent of retina specialists familiar with emerging therapy	15
6. VALUE & ACCESS	16 - 17
Overview	16
Table 6.1. Annual cost and sales of anti-VEGF therapies	16
CMS is the predominant payer for diabetic retinopathy patients	17
Figure 6.1. Payer mix for diabetic retinopathy	17
Figure 6.2. Phase III biosimilars on the horizon for Eylea and Lucentis	17
7. METHODOLOGY	18 - 20
Primary market research methodology	18
Epidemiology methodology	19

Meet the REACH Team



DANIELLE DRAYTON, PhD., Dr. Drayton is CEO and Founder of REACH Market Research. She is a seasoned business leader and pharmaceutical market researcher. Prior to founding REACH, Dr. Drayton led the Biopharma Market Assessment business at Decision Resources Group (DRG) comprised of market research, RWD analytics, and consulting business lines. In her 14 years at DRG, she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies that involved exhaustive evaluation of unmet need, target product profiles, commercial potential and new product adoption, and company competitiveness. She also has extensive experience conducting product and market opportunity assessments, portfolio analysis, product and therapeutic area strategy, product valuation and sales forecasting, and pre-launch planning. Dr. Drayton completed a postdoctoral fellowship at the Harvard Medical School, received a Ph.D. in Immunobiology from Yale University, and earned a B.S. in Microbiology and Immunology from the University of Miami (Florida).



MELISSA CURRAN is the Director of Product Management at REACH. Melissa has over 10 years of life sciences market research and consulting experience spanning from bespoke strategy consulting to syndicated market research product development and management. Prior to joining REACH, she worked at Decision Resources Group (DRG) for 7 years assisting pharmaceutical and biotechnology commercial teams across the product lifecycle to inform strategic decision making. Melissa is particularly passionate about new product planning and portfolio management, especially in the rare disease space where data can be scarce, and decision-making can be challenging. Specific types of strategic assessments Melissa specializes in include market landscape assessments, commercial opportunity assessment, patient journey mapping, product positioning and TPP optimization, portfolio prioritization, and competitive intelligence. She also has extensive experience working across various market research methodologies including qualitative interviews, quantitative surveys, patient chart audits, real world claims and EHR data, conjoint analysis and secondary research. Melissa received her bachelor's degree in Biology and minor in Business from Providence College.



MICHAEL HUGHES, MSc, Ph.D., Dr. Hughes is the Director of Research at REACH. He has worked in academia, regulatory affairs (NICE) and in RWE and epidemiology consultancies, leading the global epidemiology team at Clarivate (previously Decision Resources Group) for many years. Over that period, he has built numerous new approaches to epidemiological forecasting and imputation, which now form industry best-practice. He has built syndicated and custom epidemiological models and forecasts for many blockbuster drugs across many therapeutic areas, often using a hybrid approach sourcing data from multiple types of dataset and primary market research. He has recently worked on projects in prostate cancer, amyloidosis, anaphylaxis and multi-drug resistant UTIs, among others. He has supported the needs of both big pharma, including Novartis, GSK and Johnson and Johnson, as well as smaller companies and biotechs.

Meet the REACH Team



TYLER JAKAB, MPH is an analyst at REACH Market Research. He is responsible for conducting both primary and secondary market research regarding rare disease therapies to be integrated into market research reports for life science clients. Tyler is a recent graduate of Boston University School of Public Health where he obtained an MPH in Epidemiology of Biostatistics. Prior to joining REACH, he held roles in which he was responsible for health policy analysis, tobacco control research, and health communication. He has extensive experience in data analysis, as well as manuscript and report writing. Tyler also earned a BS in Psychology and Anthropology from the University of North Carolina at Chapel Hill.



BAYLEY KOOPMAN is a Research Associate at REACH Market Research. At REACH, Bayley supports both primary and secondary market research through literature reviews and working with qualitative data. He recently graduated from Tufts University with a B.S. in Biology where he studied the interdisciplinary OneHealth approach for public health and the environment. During this time, Bayley founded an early-stage consumer product startup, which became a finalist team in two consecutive Tufts University Entrepreneurship Pitch Competitions. Prior to joining REACH, Bayley also held roles in regulatory affairs in the rare-disease pharmaceutical industry and veterinary practice.



BRIANA MULLINS is a current PhD student At NYU School of Medicine studying the immunological progression of disease in psoriatic arthritis. She currently does both laboratory research and computational biology. Previously she earned her undergraduate degree in Biochemistry at New York University (NYU) and worked in the Blaser Lab studying the human microbiome. She also received an MSc. in Population Health at the University College London (UCL) and conducted antibiotic prescription research using the UK THIN Database. Before starting her PhD Briana worked at Decision Resources Group as an Associate Epidemiologist.